Pathway to prevention of nosocomial clostridium difficile infection

Clinical Infectious Diseases

Volumn 60, Issue , 2015, Pages S148-S158

  Goldstein, Ellie J C ^a   Johnson, Stuart ^b   Maziade, Pierre Jean ^c   McFarland, Lynne V ^d   Trick, William ^e   Dresser, Linda ^f   Millette, Mathieu ^g   Mazloum, Hadi ^g   Low, Donald E ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c Centre Hospitalier Pierre Legardeur   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Vet Aff Chicago Hlth Care Syst   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Bio K+ International Inc   (Canada)

Author keywords

Clostridium difficile; prevention; CDI; probiotic

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTIBIOTIC AGENT; CORTICOSTEROID; OPIATE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR;

BACTERIAL OVERGROWTH; CATHETER; CLOSTRIDIUM DIFFICILE INFECTION; DELPHI STUDY; DISINFECTION; ELEMENTAL DIET; ENTERIC FEEDING; ENVIRONMENTAL EXPOSURE; HAND WASHING; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MEDICAL DEVICE; PRIORITY JOURNAL; PROTECTIVE CLOTHING; REVIEW; RISK FACTOR; STAFF TRAINING; CANADA; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; EPIDEMIOLOGY; HOSPITALIZATION; PEPTOCLOSTRIDIUM DIFFICILE;

CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DELPHI TECHNIQUE; DISINFECTION; HAND HYGIENE; HOSPITALIZATION; HUMANS; PROBIOTICS; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84928881186     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ142     Document Type: Review

References (89)

1. McCollum DL, Rodriguez JM. Detection, treatment, and prevention of Clostridium difficile infection. Clin Gastroenterol Hepatol 2012; 10: 581-92.
2. Badger VO, Ledeboer NA, Graham MB, Edmiston CE Jr. Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J Parenter Enteral Nutr 2012; 36: 645-62.
3. Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14(suppl 5): 2-20.
4. Zilberberg M, Tillotson G, Kollef M, Shorr A. Update on Clostridium difficile hospitalizations in the US through 2008: the epidemic continues. Chest J 2011; 140 (4-Meeting Abstracts): 269A.
5. Kochanek KD, Xu J, Murphy SL, Minino AM, Kung H-C. Deaths: preliminary date from 2009. Natl Vital Stat Rep 2009; 59: 1-51.
6. Institut National de Santé Publique du Québec. Surveillance des diarrhées associées ? Clostridium difficile au Québec, 2012. Available at: http://www.inspq.qc.ca/pdf/publications/1536-SurvDiarrheesCDifficileQc-Bilan15aout2010Au13aout2011.pdf. Accessed 11 March 2015.
7. Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect 2008; 70: 15-20.
8. Fansi AAK, Guertin JR, LeLorier J. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. J Med Econ 2012; 15: 1-8.
9. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Shortand long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008; 46: 497-504.
10. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34: 346-53.
11. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28: 1219-27.
12. Stuart H, Cohen DNG, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Soc Healthc Epidemiol Am Infect Dis Soc A 2010; 31.
13. Floch MH, Walker A, Madsen K, et al. Recommendationsn for probiotic use-2011 update. J Clin Gastroenterol 2011; 45(suppl 3): S168-71.
14. Floch MH. Recommendations for probiotic use in humans: a 2014 update. Pharmaceuticals 2014; 7: 999-1007.
15. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibioticassociated diarrhoea. Aliment Pharmacol Ther 2012; 35: 1355-69.
16. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 878-88.
17. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; 5: CD006095.
18. Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012; 16: e786-92.
19. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105: 1636-41.
20. Beausoleil M, Fortier N, Guenette S, et al. Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 2007; 21: 732-6.
21. Sampalis J, Psaradellis E, Rampakakis E. Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea-a placebo controlled double-blind randomized, multi-center study. Arch Med Sci 2010; 6: 56-64.
22. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol 2011; 4: 185-97.
23. Safdar N, Barigala R, Said A, McKinley L. Feasibility and tolerability of probiotics for prevention of antibiotic-associated diarrhoea in hospitalized US military veterans. J Clin Pharm Ther 2008; 33: 663-8.
24. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335: 80.
25. Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012; 107: 922-31.
26. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
27. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29: 44-50.
28. Kachrimanidou M, Malisiovas N. Clostridium difficile infection: a comprehensive review. Crit Rev Microbiol 2011; 37: 178-87.
29. Birgand G, Miliani K, Carbonne A, Astagneau P. Is high consumption of antibiotics associated with Clostridium difficile polymerase chain reaction-ribotype 027 infections in France? Infect Control Hosp Epidemiol 2010; 31: 302-5.
30. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57: 2326-32.
31. Aldeyab MA, Kearney MP, Scott MG, et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012; 67: 2988-96.
32. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2168-74.
33. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
34. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51: 1339-50.
35. Baskerville A, Batter-Hatton D. Intestinal lesions induced experimentally by methotrexate. Br J Exp Pathol 1977; 58: 663-9.
36. Raza S, Baig MA, Russell H, Gourdet Y, Berger BJ. Clostridium difficile infection following chemotherapy. Recent Pat Anti Infect Drug Discov 2010; 5: 1-9.
37. Allan SG, Smyth JF. Small intestinal mucosal toxicity of cis-platinum- comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 1986; 53: 355-60.
38. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficileassociated diarrhea and proton pump inhibitor therapy: a metaanalysis. Am J Gastroenterol 2012; 107: 1001-10.
39. Ahmed Samie A, Traub M, Bachmann K, Kopischke K, Theilmann L. Risk factors for recurrence of Clostridium difficile-associated diarrhea. Hepatogastroenterology 2012; 60: 1351-4.
40. Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012: 1538-42.
41. McGuire T, Dobesh P, Klepser D, Rupp M, Olsen K. Clinically important interaction between statin drugs and Clostridium difficile toxin? Med Hypotheses 2009; 73: 1045-7.
42. Mora AL, Salazar M, Pablo-Caeiro J, et al. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci 2012; 343: 277-80.
43. Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother 2006; 50: 3216-9.
44. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-64.
45. Mayumi T, Takezawa J, Takahashi H, et al. IL-15 is elevated in the patients of postoperative enterocolitis. Cytokine 1999; 11: 888-93.
46. Murabata M, Kato H, Yano H, et al. Intestinal colonization and nosocomial spread of Clostridium difficile in pediatric cancer patients under long-term hospitalization [in Japanese]. Kansenshogaku Zasshi 2008; 82: 419-26.
47. El-Mahallawy HA, El-Din NHA, Attia IA, El-Haddad A. Clostridium difficile associated diarrhea in pediatric oncology patients receiving chemotherapy. J Egyptian Nat Cancer Inst 2001; 13: 285-90.
48. Schuller I, Saha V, Lin L, Kingston J, Eden T, Tabaqchali S. Investigation and management of Clostridium difficile colonisation in a paediatric oncology unit. Arch Dis Child 1995; 72: 219-22.
49. O'Keefe SJ. Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol 2010; 16: 139-42.
50. Iizuka M, Itou H, Konno S, et al. Elemental diet modulates the growth of Clostridium difficile in the gut flora. Aliment Pharmacol Ther 2004; 20(suppl 1): 151-7.
51. Vrtis MC. Clostridium difficile: preventing epidemic outbreaks in home health. Home Healthc Nurse 2008; 26: 563-9; quiz 70-1.
52. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
53. Yokohama S, Aoshima M, Asama T, Shindo J, Maruyama J. Clostridium difficile-associated enteric disease after percutaneous endoscopic gastrostomy. J Gastroenterol 2009; 44: 121-5.
54. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012; 7: e34938.
55. Avadhani A, Miley H. Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficile-associated disease in hospitalized adults-a meta-analysis. J Am Acad Nurse Pract 2011; 23: 269-74.
56. McFarland LV. Evidence-based review of probiotics for antibioticassociated diarrhea and Clostridium difficile infections. Anaerobe 2009; 15: 274-80.
57. Maziade PJ, Andriessen JA, Pereira P, Currie B, Goldstein EJ. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013; 29: 1341-7.
58. Millette M, Saint-Pierre G, Frappier M, Richard J, Diaz K, Carrière S. Antimicrobial and anticytotoxic capacity of a probiotic formula of Lactobacillus acidophilus CL1285 and L. casei LBC80R against Clostridium difficile NAP1/027/BI. In: 11th Biennial Congress of the Anaerobe Society of the Americas, San Francisco, CA, 2012.
59. Millette M, Nguyen A, Amine KM, Lacroix M. Gastrointestinal survival of bacteria in commercial probiotic products. Int J Probiotics Prebiotics 2013; 8: 149-56.
60. Dubberke ER, Gerding DN. Rationale for hand hygiene recommendations after caring for a patient with Clostridium difficile infection. Soc Healthc Epidemiol Am 2011. Available at: http://www.shea-online.org/View/ArticleId/109/Rationale-for-Hand-Hygiene-Recommendationsafter-Caring-for-a-Patient-with-Clostridium-difficile-Inf.aspx. Accessed 11 March 2015.
61. Boyce JM, Pittet D; Healthcare Infection Control Practices Advisory Committee. Society for Healthcare Epidemiology of America. Association for Professionals in Infection Control. Infectious Diseases Society of America. Hand Hygiene Task Force. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002; 23(suppl 12): S3-40.
62. Samore MH, Venkataraman L, DeGirolami PC, Arbeit RD, Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996; 100: 32-40.
63. Gould D. Prevention and control of Clostridium difficile infection. Nurs Older People 2010; 22: 29-34; quiz 5.
64. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29(suppl 1): S81-92.
65. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46(suppl 1): S43-9.
66. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am 2009; 23: 727-43.
67. Saskatchewan Infection Prevention and Control Program. Guidelines for the management of Clostridium difficile infection (CDI) in all healthcare settings. Saskatchewan Ministry of Health, 2011.
68. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother 2007; 59: 990-5.
69. Brakovich B, Bonham E, Vanbrackle L. War on the spore: Clostridium difficile disease among patients in a long-term acute care hospital. J Healthc Qual 2012; 35: 15-21.
70. Gerding DN, Muto CA, Owens RC. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46(suppl 1): S43-9.
71. Macleod-Glover N, Sadowski C. Efficacy of cleaning products for C. difficile: environmental strategies to reduce the spread of Clostridium difficile-associated diarrhea in geriatric rehabilitation. Can Fam Physician 2010; 56: 417-23.
72. Boyce JM, Havill NL, Otter JA, et al. Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol 2008; 29: 723-9.
73. Butler M, Bliss D, Drekonja D, et al. Effectiveness of early diagnosis, prevention, and treatment of Clostridium difficile infection. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
74. Carroll KC. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe 2011; 17: 170-4.
75. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46(suppl 1): S12-8.
76. Svensson AM, LaSala PR; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology consultation on detection of Clostridium difficile. Am J Clin Pathol 2012; 137: 10-5.
77. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992; 166: 561-7.
78. Goldstein EJ, Polonsky J, Touzani M, Citron DM. C. difficile infection (CDI) in a long-term acute care facility (LTAC). Anaerobe 2009; 15: 241-3.
79. Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcareassociated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol 2010; 105: 2327-39; quiz 40.
80. Pogorzelska M, Stone PW, Larson EL. Certification in infection control matters: impact of infection control department characteristics and policies on rates of multidrug-resistant infections. Am J Infect Control 2012; 40: 96-101.
81. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990; 88: 137-40.
82. Bryce BLJE. Hospital infection control strategies for vancomycinresistant Enterococcus, methicillin-resistant Staphylococcus aureus and Clostridium difficile. Can Med Assoc J 2009; 180: 627-31.
83. Perry C, Marshall R, Jones E. Bacterial contamination of uniforms. J Hosp Infect 2001; 48: 238-41.
84. Health Protection Agency and Department of Health. Clostridium difficile infection: how to deal with the problem. Available at: http://www. hpa.org.uk/webc/HPAwebFile/HPAweb-C/1232006607827. Accessed 11 March 2015.
85. Rawding P, Ross SR, Davis I, et al. Lessons learned following a Clostridium difficile outbreak in acute care. Nova Scotia Health and Wellness (ICPNS), 2011.
86. Ontario Ministry of Health and Long-term Care . Clostridium difficile. Available at: http://health.gov.on.ca/en/ccom/cdi/outbreak.aspx. Accessed 11 March 2015.
87. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A casecontrol study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008; 62: 388-96.
88. Kutty PK, Woods CW, Sena AC, et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010; 16: 197-204.
89. Lambert PJ, Dyck M, Thompson LH, Hammond GW. Populationbased surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol 2009; 30: 945-51.